Medicine Drip icon

GLASSIA® can be infused in a clinic, at an outpatient infusion center, or at home by a healthcare provider or self-infusion. You and your doctor can choose the infusion option that fits your life. Explore infusion options

*If self-administration is deemed appropriate, ensure that you receive detailed instructions and adequate training on how to administer at home or other appropriate setting and have demonstrated the ability to independently administer GLASSIA.


Having the option to infuse at home on my own* gives me the flexibility to keep doing the things I love, like spending time with my grandchildren.”

Actual GLASSIA patient for ~3 years
View Trudy’s Story
paper airplane icon
Want updates on Alpha-1 deficiency and GLASSIA? Sign up below for more info

Alpha-1 antitrypsin deficiency is sometimes referred to as just Alpha-1 deficiency.

headset icon
OnePath is personalized product support after you and your doctor have chosen GLASSIA.
Learn about product support


Managing Alpha-1 deficiency begins with understanding it.

Lungs icon

Alpha-1 antitrypsin is a protein that helps protect the lungs

Alpha-1 antitrypsin circulates in your bloodstream and helps protect the elastic structures of your lungs from an enzyme that can attack normal body tissue. Without enough functional Alpha-1 antitrypsin, lung damage can develop, usually in people between 20 and 50 years of age.

Liquid icon

Emphysema can be caused by a severe Alpha-1 deficiency

A severe Alpha-1 deficiency can lead to emphysema—a lung condition that causes shortness of breath—with symptoms that can worsen over time.

Branch icon

Alpha-1 deficiency can run in families

Alpha-1 deficiency is caused by a genetic mutation that occurs in about 1 in every 3,000 to 5,000 people in the U.S. It’s also the most common genetic cause of emphysema.

You are not alone.

~1 in every 3,000 to 5,000 Americans lives with Alpha-1 deficiency.

Talk to your doctor if you have questions about family testing, living with Alpha-1 deficiency, or augmentation therapy.


If you and your doctor have decided to treat your Alpha-1 deficiency with GLASSIA, begin with the basics on how GLASSIA works—and then explore options for your infusion experience.

Chart icon

GLASSIA increases the levels of the Alpha-1 antitrypsin protein in your blood and lungs

The Alpha-1 antitrypsin protein protects the lung tissue by blocking certain enzyme-caused damage. Such damage can lead to severe lung disease, such as emphysema.

Alpha-1 antitrypsin augmentation is chronic maintenance therapy. So, GLASSIA is typically given once every week to increase levels of Alpha-1 antitrypsin in your blood and lungs.

Drip icon

GLASSIA is ready to infuse

GLASSIA is an intravenous (into a vein) infusion that generally takes about 15 minutes at the recommended dose and maximum infusion rate.

Bell icon

GLASSIA puts you in control of your infusion experience

GLASSIA’s flexibility of administration lets you decide where you want to infuse. Talk to your healthcare provider about which administration option works best for you:

  • In the clinic by a healthcare provider
  • At an outpatient infusion center
  • At home by a healthcare provider
  • At home through self-infusion or by a caregiver—after appropriate training

If self-administration is deemed appropriate, ensure that you receive detailed instructions and adequate training on how to administer at home or other appropriate setting and have demonstrated the ability to independently administer GLASSIA.


When you’re prescribed GLASSIA, OnePath dedicated product support is here for you.

At OnePath, we see a person, not a patient.

We know that living with Alpha-1 deficiency looks different for everyone. We get to know you, understand who you are, and learn what’s important to you—so that we can focus on what you specifically need when it comes to your prescribed Takeda therapy.

Your Patient Support Manager (PSM) can address your questions and concerns and help determine next steps. They can also:

Work with your insurance provider, specialty pharmacy, and site of care to help you receive your GLASSIA treatment

Enroll you in the OnePath Co-Pay Assistance Program, if you qualify§

Arrange for a trained nursing professional to teach you or a caregiver how to infuse your GLASSIA treatment at home, if requested by your healthcare provider

Connect you with other dedicated OnePath specialists as needed

Continue to help support you throughout your GLASSIA treatment, even after you have started on therapy

Direct you to community support resources and advocacy organizations

The OnePath Co-Pay Assistance Program can help you save on your prescribed Takeda treatment.

The program can cover up to 100% of your out-of-pocket co-pay costs, if you’re eligible. To be eligible for this program, you must:

  1. Be prescribed a Takeda treatment for a condition it’s approved by the Food and Drug Administration (FDA) to treat. This is called an “approved indication.” Ask your healthcare provider if you’re not sure.
  2. Have commercial insurance. This includes Health Insurance Marketplace plans.
    • Commercial insurance does not include Medicare, Medicaid, Veterans Affairs (VA), or other federal or state health plans
  3. Be enrolled in OnePath.
Have questions? Call OnePath at 1-866-888-0660, Monday through Friday, 8:30 AM to 8:00 PM ET, or visit
If English is not your preferred language, let us know. We can communicate with you over the phone using a translation service.

§To be eligible, you must be enrolled in OnePath and have commercial insurance. Other terms and conditions apply. Call OnePath for more details.

IMPORTANT NOTICE: The OnePath Co-Pay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Copayment assistance under the Program is not transferable. The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes, you must notify the Program immediately at 1-866-888-0660. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.

How to get started

  1. Your doctor will complete the enrollment form
  2. You need to sign the Patient Authorization section
  3. OnePath will confirm your eligibility
  4. Your dedicated PSM will call you from 1-866-888-0660
Visit OnePath

Stay in touch

Sign up, and we’ll make sure you get the latest information about Alpha-1 deficiency and GLASSIA.

*Indicates a required field.

Are you currently on GLASSIA therapy?*

Are you currently on another augmentation therapy?*

What is GLASSIA?

GLASSIA is a medicine containing human Alpha1-Proteinase Inhibitor (Alpha1-PI) that is used to treat adults with lung disease (emphysema) because of severe Alpha1-antitrypsin (Alpha1) deficiency. GLASSIA is not meant to be used as a therapy for lung disease other than severe Alpha1 deficiency. Effects of GLASSIA on worsening lung function and emphysema progression have not been proven in clinical trials. Long-term effects of Alpha1 replacement and maintenance therapy have not been studied.

Back to Top BACK TO TOP


GLASSIA is a medicine used to treat adults with lung disease (emphysema) caused by severe Alpha1-antitrypsin (AAT) deficiency. GLASSIA increases the levels of the AAT protein in your blood and lungs ... . It is not known if increasing AAT levels with GLASSIA affects worsening lung function or emphysema progression. Long-term effects of AAT therapy with GLASSIA have not been studied. Please see full Indication and Limitations of Use below.


What is the most important information I need to know about GLASSIA?

  • GLASSIA can cause severe allergic reactions including hives, swelling in the mouth or throat, itching, tightness in the chest, trouble breathing, wheezing, faintness or low blood pressure See more safety info.